Allergoids

Extracts of allergens, or purified allergens that have been chemically modified to reduce their ability to induce IGE-MEDIATED HYPERSENSITIVITY (allergenicity) while increasing their ability to induce IMMUNE TOLERANCE.

Also Known As:

Networked: 106 relevant articles (20 outcomes, 27 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Zielen, Stefan: 6 articles (12/2019 - 02/2010)
2.	Falagiani, P: 5 articles (12/2011 - 07/2006)
3.	Rosewich, Martin: 4 articles (12/2019 - 02/2010)
4.	Mistrello, G: 4 articles (07/2012 - 03/2005)
5.	Klimek, Ludger: 3 articles (01/2021 - 01/2018)
6.	Casanovas, Miguel: 3 articles (10/2018 - 02/2016)
7.	Cases, Bárbara: 3 articles (10/2018 - 02/2016)
8.	Fernández-Caldas, Enrique: 3 articles (10/2018 - 02/2016)
9.	Klimek, L: 3 articles (01/2018 - 08/2003)
10.	Mistrello, Gianni: 3 articles (01/2016 - 04/2008)

Related Diseases

1.	Asthma (Bronchial Asthma) 01/01/2019 - "This real-life study evaluated the effect of six AITs (native pollen SLIT/SCIT, four allergoid SCITs) vs symptomatic medication use, on AR symptoms and asthma symptoms/onset, in patients with birch pollen-associated AR and/or asthma. " 01/01/2018 - "We performed an analysis of pooled safety data for subcutaneous AIT (SCIT) with a high-dose house dust mite allergoid from 6 randomized, controlled trials (RCT) in HDM allergic respiratory disease (ARD) and of post marketing safety data from more than 10 years including different subgroups (age, gender, asthma status). " 01/01/2018 - "Efficacy and tolerability of a house dust mite allergoid in allergic bronchial asthma: a randomized dose-ranging trial." 01/01/2020 - "After up to 6 years of follow-up, patients treated with mite allergoid required significantly fewer AR and asthma prescriptions (59.7% vs 10.8%) than the control group, and the probability of asthma development was significantly lower. " 04/01/2015 - "In conclusion, both monomeric allergoid dosages of SLIT (2000 UI and 4000 UI) are a safe and efficacy option to reduce symptoms in patients with allergic asthma caused by house dust mites. "
2.	Hypersensitivity (Allergy) 07/01/2012 - "Sublingual immunotherapy with monomeric carbamylated allergoid (LAIS) is an effective and well tolerated treatment of respiratory allergy. " 03/01/2010 - "The allergoid SLIT was shown to be effective and safe in Olea allergy in particular when a coseasonal regimen was used." 12/01/2011 - "Sublingual immunotherapy (SLIT) with monomeric carbamylated allergoid proved to be well tolerated, safe and effective in patients with respiratory allergy. " 01/01/2021 - "Patients with allergy received standard preseasonal subcutaneous AIT with allergoids to birch and/or grass. " 01/01/2018 - "In the last years, the partial understanding of the mechanism of action and the generation of clinical evidence of different types of allergoids, linked to their excellent safety profile and their convenience for a quick build up phase, have made of allergoids an excellent product for allergy treatment."
3.	Rhinitis 07/01/2006 - "Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites." 02/01/1990 - "Symptoms and medications for rhinitis and asthma were studied during the season, and both groups receiving allergoids had a significant reduction of symptom-medication scores for nasal and bronchial symptoms. " 07/01/2010 - "We assessed the clinical effects of a monomeric allergoid across 3 different maintenance doses in mite-monosensitized patients with rhinitis and intermittent asthma. " 02/01/2007 - "Evaluation of the antiinflammatory and clinical effects of sublingual immunotherapy with carbamylated allergoid in allergic asthma with or without rhinitis. " 07/01/2005 - "We studied 105 patients: 28 children (20 male, mean age 13.3 +/- 2.1 yr) and 77 adults (29 male, mean age 34.7 +/- 9.9 years) with a history of intermittent/persistent rhinitis or intermittent/mild persistent asthma due to House Dust Mite (n = 56), Parietaria (n = 34) and Timothy-grass (n = 15) The build-up ultra-rush phase involved the administration, every five minutes, of increasing doses of the sublingual allergoid SLIT. "
4.	Seasonal Allergic Rhinitis (Hay Fever) 11/01/1983 - "[Advantages of hyposensitization with a high dose of allergoid in pollen allergy]." 12/01/1981 - "IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever." 10/01/1989 - "Specific immunotherapy with unmodified formalinized allergoids is effective in grass-pollen allergy, but systemic reactions have been observed. " 01/01/1987 - "Specific immunotherapy is effective in grass pollen allergy with standardized extracts and formalinized allergoids; but systemic reactions are not uncommon. " 03/01/2005 - "Efficacy of sublingual coseasonal immunotherapy with a monomeric allergoid in Cupressaceae pollen allergy--preliminary data."
5.	Allergic Rhinitis 05/04/2007 - "However, in patients with grass pollen-sensitive intermittent allergic rhinitis, platelet release reaction in vivo, measured by beta-TG, did not change significantly during the dose increase phase of subcutaneous SIT with grass pollen allergoids. " 11/17/2006 - "Twelve grass-pollen allergic patients (seven men and five women) with intermittent allergic rhinitis were treated with specific subcutaneous allergoid preparation. " 08/01/1977 - "In a pilot study, five adult patients with allergic rhinitis due to grass pollen underwent local intranasal hyposensitization with a chemically modified grass pollen extract--a so-called allergoid. " 01/01/2014 - "The aim of this study was to evaluate the basophil response, which can explain early clinical findings of short-term preseasonal allergoid immunotherapy in allergic rhinitis. " 06/27/2023 - "Subcutaneous Immunotherapy (SCIT) with the New Polymerized Molecular Allergoid Alt a1: A Pilot Study in Children with Allergic Rhinitis Sensitized to Alternaria Alternata."

Related Drugs and Biologics

1.	Allergens
2.	Cytokines
3.	Tyrosine (L-Tyrosine)
4.	monophosphoryl lipid A
5.	Steroids
6.	Vaccines
7.	Immunoglobulin E (IgE)
8.	Ovalbumin
9.	N,N,N',N'- tetramethyl- N''- (4- nitrophenyl)phosphoric triamide
10.	potassium cyanate (KNCO)

Related Therapies and Procedures

1.	Immunotherapy
2.	Injections
3.	Therapeutics
4.	Premedication